Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine in healthy children.
This study is a randomized, blind, controlled phase III clinical trial. The purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The control is diluent of lyophilized vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. All participants are healthy, and will be randomly assigned into experimental group or control group in the ratio 1:1.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental Group | Experimental |
|
|
| Control Group | Sham Comparator |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Investigational live attenuated varicella vaccine | Biological | The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The incidences of varicella of each group | The first 30 cases of varicella occurred 30 days after injection will be collected. | ≥30 cases reported 30 days after injection |
| The protection rate of the vaccine | The protection rate will be calculated based on the reported cases occurred 30 days after injection. | ≥30 cases reported after 30 days of the injection |
| Measure | Description | Time Frame |
|---|---|---|
| The incidences of adverse events (AEs) of each group | AEs occurred within 30 days after injection will be collected. | 30 days |
| The incidences of serious adverse events (SAEs) of each group | SAEs occurred within 6 months after injection will be collected. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Prior vaccination with varicella vaccine or with history of varicella zoster virus (VZV) infection;
Axillaty temperature > 37.0 °C;
History of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc;
History of epilepsy, seizures or convulsions, or a family history of mental illness, autoimmune disease or immunodeficiency;
Severe malnutrition, congenital malformation, developmental disorders, or serious chronic diseases;
Acute disease or acute stage of chronic disease within 7 days prior to study entry;
Receipt of any of the following products:
Any significant abnormity of heart, lung, skin, or pharynx;
Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shengli Xia | Henan Provincial Center for Disease Control and Prevention | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xiangcheng County Center for Disease Control and Prevention | Xuchang | Henan | 461700 | China | ||
| Biyang County Center for Disease Control and Prevention |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35632416 | Derived | Zhang Y, Wang L, Wang Y, Zhang W, Jia N, Xie Z, Huang L, You W, Lu W, Li E, Gao F, Hu Y, Meng F, Xia S. Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years. Vaccines (Basel). 2022 Apr 22;10(5):660. doi: 10.3390/vaccines10050660. | |
| 30616012 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002644 | Chickenpox |
| ID | Term |
|---|---|
| D000073618 | Varicella Zoster Virus Infection |
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| diluent of lyophilized vaccine | Biological | The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. |
|
| 6 months |
| The seroconversion rate of the immunogenicity group | Seroconversion rate of the immonogenicity group 30 days after injection will be collected. | 30 days after injection |
| The geometric mean titer (GMT) of the immunogenicity group | Geometric mean titer (GMT) of the immonogenicity group will be collected before and 30 days after injection. | 30 days |
| The geometric mean fold increase (GMI) of the immunogenicity group | Geometric mean fold increse (GMI) of the immonogenicity group will be calculated based on the geometric mean titer. | 30 days after injection |
| Zhumadian |
| Henan |
| 463700 |
| China |
| Hao B, Chen Z, Zeng G, Huang L, Luan C, Xie Z, Chen J, Bao M, Tian X, Xu B, Wang Y, Wu J, Xia S, Yuan L, Huang J. Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial. Clin Microbiol Infect. 2019 Aug;25(8):1026-1031. doi: 10.1016/j.cmi.2018.12.033. Epub 2019 Jan 4. |
| D007239 | Infections |